Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer

Breast Cancer: Targets and Therapy · Published 2026-06-01 · DOI 10.2147/bctt.s574628

Free full text

Authors (7)

Yujing Tan, Cheng Zeng, Jiuda Zhao, Weihong Zhao, Hanfang Jiang, Jiani Wang, Fei Ma

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Tan, Y., Zeng, C., Zhao, J., et al. (2026). Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer. Breast Cancer: Targets and Therapy. https://doi.org/10.2147/bctt.s574628

Related articles